Long-term active surveillance for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a prostate (this includes cisgender men and transgender women who have never used hormone blockers).
- You had a special MRI scan to find and measure your cancer.
- You had a biopsy (needle samples) taken from your prostate, which showed localized (not spread) prostate cancer.
- You and your doctor have chosen active surveillance as your plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well “active surveillance” works for men with prostate cancer who are considered higher risk because of family history or genetics. It aims to safely monitor the cancer and decide the best timing for treatment if needed, while tracking side effects and follow-up success.
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
This trial studies a “watchful waiting” approach, where doctors closely monitor certain prostate cancers with regular checkups and repeat biopsies. It may help people avoid or delay treatment side effects while watching for signs the cancer needs treatment.
This study uses special prostate MRI scans to see how prostate cancer changes over time while you stay on active surveillance. It also looks at prostate tissue to understand your cancer’s genetics, which may help guide future decisions.
This study checks whether people with a low chance of prostate cancer can be monitored closely without having an immediate prostate biopsy. It uses PSA blood tests and prostate MRI to sort who may safely wait.
This trial follows men with prostate cancer who choose “active surveillance” instead of immediate treatment. It tests whether careful tracking (including patient reports) can help manage cancer over time and guide decision-making.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.